Trial of a selective acetylcholinesterase inhibitor, galanthamine hydrobromide, in the treatment of chronic fatigue syndrome

Journal of Chronic Fatigue Syndrome

Volumn 2, Issue 2-3, 1996, Pages 35-54

  Snorrason, Emir ^a,c   Geirsson, Arni ^a   Stefansson, Kari ^b  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NONE   (Iceland)

Author keywords

cholinergic deficit; Chronic fatigue syndrome; galanthamine

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; PLACEBO;

ADULT; AGED; ANXIETY; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; FEMALE; HEADACHE; HUMAN; INTELLIGENCE TEST; MALE; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PATHOGENESIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECALL; SLEEP DISORDER; SLEEP STAGE; TABLET; VERTIGO; VOMITING;

EID: 0029836258     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v02n02_04     Document Type: Conference Paper

References (3)

1. Sharpe MC, Archard LC, Banatvala JE, et al. Chronique fatigue syndrome: guidelines for research. Journal of the Royal Society of medicine. 1991;84:118-21.
2. Schluedeberg A, Straus SE, Peterson P, et al. Chronic Fatigue Syndrome Research. Definition and Medical Outcome Assessment. Ann Intern Med, 1992; 117: 325-331.
3. Shafran SD. The Chronique Fatigue Syndrome. Am J Med, 1991; 90: 730-39